Renal Lipotoxicity: Mechanisms and Therapeutic Perspectives

Area of Science:

• Nephrology
• Metabolic Syndrome
• Lipid Metabolism

Background:

• Renal lipotoxicity, toxic lipid accumulation in kidney cells, is a major factor in chronic kidney disease (CKD), particularly in diabetic individuals.
• Metabolic factors like insulin resistance, hyperglycemia, and dyslipidemia disrupt kidney lipid metabolism, causing cell damage, mitochondrial dysfunction, and fibrosis, contributing to cardiovascular-kidney-metabolic (CKM) syndrome.

Purpose of the Study:

• To synthesize evidence on the mechanisms of renal lipotoxicity in CKD and CKM syndrome.
• To explore the role of lipid dysregulation in diabetic kidney disease (DKD).
• To review emerging therapeutic strategies targeting lipid metabolism for kidney protection.

Main Methods:

• Review of current scientific literature on renal lipotoxicity, DKD, and CKM syndrome.
• Analysis of molecular and cellular pathways involved in kidney lipid metabolism.
• Evaluation of therapeutic interventions targeting lipid dysregulation.

Main Results:

• Dysregulated lipid transporters (CD36, FATPs, FABPs) and lipogenic factors (SREBPs, ChREBP) increase lipid uptake and synthesis in the kidney.
• Impaired fatty acid oxidation (PPARα downregulation) and cholesterol efflux (ABCA1, ABCG1) exacerbate lipid accumulation.
• Cell-specific injuries, mitochondrial dysfunction, oxidative stress, and fibrosis are key consequences of renal lipotoxicity.
• Numerous therapeutic strategies, including lifestyle changes and medications (SGLT2 inhibitors, GLP-1 RAs, statins, etc.), show promise in restoring lipid homeostasis and preserving kidney function.

Conclusions:

• Renal lipotoxicity is a critical link between systemic metabolic dysfunction and CKD progression.
• Targeting renal lipotoxicity presents a promising therapeutic avenue for DKD and CKM syndrome.
• Integrated metabolic and renal management strategies are essential for addressing these conditions.